Ada Bertoli
Overview
Explore the profile of Ada Bertoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armenia D, Carioti L, Micheli V, Bon I, Allice T, Bonura C, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339898
Background: Next-generation sequencing (NGS) is gradually replacing Sanger sequencing for HIV genotypic drug resistance testing (GRT). This work evaluated the concordance among different NGS-GRT interpretation tools in a real-life setting....
2.
Fabeni L, Armenia D, Abbate I, Gagliardini R, Mazzotta V, Bertoli A, et al.
J Antimicrob Chemother
. 2024 Jul;
79(9):2152-2162.
PMID: 39028674
Background: Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care. Methods: Overall, 2386...
3.
Giammarino F, De Salazar A, Malet I, Vinuela L, Fuentes A, Saladini F, et al.
J Infect Dis
. 2024 Jan;
229(6):1796-1802.
PMID: 38206187
Background: Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine. Methods: Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and...
4.
Salpini R, Piermatteo L, Torre G, DAnna S, Khan S, Duca L, et al.
Int J Infect Dis
. 2023 Nov;
138:1-9.
PMID: 37944585
Objectives: Here we investigate Hepatitis D virus (HDV)-prevalence in Italy and its fluctuations over time and we provide an extensive characterization of HDV-infected patients. Methods: The rate of HDV seroprevalence...
5.
Piermatteo L, DAnna S, Bertoli A, Bellocchi M, Carioti L, Fabeni L, et al.
Emerg Microbes Infect
. 2023 Jun;
12(1):2219347.
PMID: 37288750
Specific HBsAg mutations are known to hamper HBsAg recognition by neutralizing antibodies thus challenging HBV-vaccination efficacy. Nevertheless, information on their impact and spreading over time is limited. Here, we characterize...
6.
Armenia D, Santoro M, Charpentier C, Bertoli A, Forbici F, Calvez V, et al.
J Antimicrob Chemother
. 2023 May;
78(6):1415-1422.
PMID: 37258034
Background: This work aims to evaluate integrase resistance and its predictors in HIV-1 infected combined antiretroviral therapy (cART) experienced individuals failing a dolutegravir-based regimen. Methods: Major resistance mutations (MRM) and...
7.
Costanza G, Paba P, Ciotti M, Ombres D, Di Carlo S, Marcuccilli F, et al.
Biomolecules
. 2022 Jul;
12(7).
PMID: 35883543
Background: In the last two years, the SARS-CoV-2 pandemic has determined radical changes in human behaviors and lifestyles, with a drastic reduction in socialization due to physical distancing and self-isolation....
8.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, et al.
J Glob Antimicrob Resist
. 2022 Jul;
30:326-334.
PMID: 35793776
Objectives: We evaluated virological response and resistance profiles in individuals who were virologically suppressed who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real life. Methods: Survival analysis was used to assess...
9.
Vergni D, Santoni D, Bouba Y, Lemme S, Fabeni L, Carioti L, et al.
Infect Genet Evol
. 2022 May;
101:105294.
PMID: 35513162
This study aimed at updating previous data on HIV-1 integrase variability, by using effective bioinformatics methods combining different statistical instruments from simple entropy and mutation rate to more specific approaches...
10.
Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, et al.
Biomedicines
. 2022 Feb;
10(2).
PMID: 35203653
The role of novel HBV markers in predicting Hepatitis B virus reactivation (HBV-R) in HBsAg-negative/anti-HBc-positive oncohaematological patients was examined. One hundred and seven HBsAg-negative/anti-HBc-positive oncohaematological patients, receiving anti-HBV prophylaxis for...